Bcl-xL antisense treatment sensitizes Bcl-xL-overexpressing squamous cell carcinoma cells to carboplatin

Oral Oncology

Volumn 38, Issue 8, 2002, Pages 752-756

  Itoh, M ^a   Noutomi, T ^b   Chiba, H ^c   Mizuguchi, J ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antisense; Bcl xL; CBDCA; Squamous cell carcinoma

Indexed keywords

CARBOPLATIN; OLIGONUCLEOTIDE; PROTEIN BCL XL; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCL2L1 PROTEIN, HUMAN; PROTEIN BCL 2; PROTEIN BCL X;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CANCER RESISTANCE; CANCER THERAPY; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN FAMILY; SQUAMOUS CELL CARCINOMA; TISSUE SPECIFICITY; CELL CULTURE; CELL DIVISION; DRUG COMBINATION; DRUG RESISTANCE; GENETICS; METABOLISM; MOUTH TUMOR; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; MOUTH NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0036986695     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(02)00047-7     Document Type: Article

References (24)

1. Zamboglou N., Schnabel T., Kolotas C., Achterrath W., Strehl H., Dalhauser S.et al. Carboplatin and radiotherapy in the treatment of head and neck cancer: six years' experience. Seminars in Oncology. 21:1994;45-53.
2. Niitani H., Kobayashi K. Cisplatin/carboplatin therapy in non-small cell lung cancer. Oncology. 49(Suppl 1):1992;51-56.
3. Brockstein B.E., Vokes E.E. Oral chemotherapy in head and neck cancer. Drugs. 58(Suppl 3):1999;91-97.
4. Eastman A. Mechanisms of resistance to cisplatin. Cancer Treatment and Research. 57:1991;233-249.
5. Costantini P., Jacotot E., Decaudin D., Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. Journal of The National Cancer Institute. 92:2000;1042-1053.
6. Antonsson B., Martinou J.C. The Bcl-2 protein family. Experimental Cell Research. 256:2000;50-57.
7. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes and Development. 13:1999;1899-1911.
8. Reed J.C., Kroemer G. Mechanisms of mitochondrial membrane permeabilization. Cell Death and Differentiation. 7:2000;1145.
9. Itoh M., Chiba H., Noutomi T., Takada E., Mizuguchi J. Cleavage of Bax-alpha and Bcl-x(L) during carboplatin-mediated apoptosis in squamous cell carcinoma cell line. Oral Oncology. 36:2000;277-285.
10. Reed J.C. Bcl-2 family proteins. Oncogene. 17:1998;3225-3236.
11. Marzo I., Brenner C., Zamzami N., Jurgensmeier J.M., Susin S.A., Vieira H.L.et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 281:1998;2027-2031.
12. Shimizu S., Narita M., Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 399:1999;483-487.
13. Noutomi T., Chiba H., Itoh M., Toyota H., Mizuguchi J. Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncology. 38:2002;41-48.
14. Decaudin D., Geley S., Hirsch T., Castedo M., Marchetti P., Macho A.et al. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Research. 57:1997;62-67.
15. Simonian P.L., Grillot D.A., Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood. 90:1997;1208-1216.
16. McNeil P.L., Murphy R.F., Lanni F., Taylor D.L. A method for incorporating macromolecules into adherent cells. Journal of Cell Biology. 98:1984;1556-1564.
17. Partridge M., Vincent A., Matthews P., Puma J., Stein D., Summerton J. A simple method for delivering morpholino antisense oligos into the cytoplasm of cells. Antisense and Nucleic Acid Drug Development. 6:1996;169-175.
18. Summerton J., Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense and Nucleic Acid Drug Development. 17:1997;187-195.
19. Beale P.J., Rogers P., Boxall F., Sharp S.Y., Kelland L.R. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. British Journal of Cancer. 82:2000;436-440.
20. Jansen B., Schlagbauer-Wadl H., Brown B.D., Bryan R.N., van Elsas A., Muller M.et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Medicine. 4:1998;232-234.
21. Simoes-Wust A.P., Olie R.A., Gautschi O., Leech S.H., Haner R., Hall J.et al. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells. International Journal of Cancer. 87:2000;582-590.
22. Fennell D.A., Corbo M.V., Dean N.M., Monia B.P., Cotter F.E. In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model. British Journal of Haematology. 112:2001;706-713.
23. Thierry A.R., Dritschilo A. Liposomal delivery of antisense oligodeoxynucleotides. Application to the inhibition of the multidrug resistance in cancer cells. Annals of The New York Academy of Sciences. 669:1992;300-302.
24. Spiller D.G., Tidd D.M. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Research and Development. 5:1995;13-21.